α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Pharmacological characterization of the small molecule 03A10 as an inhibitor of α-synuclein aggregation for Parkinson's disease treatment
Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration, Acta Neuropathologica Communications
Distribution of α-Synuclein Aggregation in the Peripheral Tissues
IJMS, Free Full-Text
Parkinson's Disease Therapies Targeting Alpha Synuclein
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.
Alleviating toxic α-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson's disease, Molecular Brain
p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1
Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson's disease-like pathology: Molecular Therapy - Nucleic Acids
α-Synuclein Aggregation in Treatment of Parkinson's Disease
Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease
de
por adulto (o preço varia de acordo com o tamanho do grupo)
